The companies behind controversial puberty blockers at the centre of a landmark transgender ruling have seen their share prices dip.
The firms, AbbVie Inc and Takeda, saw the value of their shares fall in the aftermath of the Kiera Bell case.
Ten grounds for appeal put forward by those who lost the case, the Tavistock and Portman NHS Trust, were also all refused.
